The global Urology Drugs Market is expected to exceed US$ 6.40 Billion by 2028, with CAGR at 6.4% in the given forecast period.
Lower urinary tract symptoms are not a disease that can affect survival, but are closely related to quality of life and form a huge drug market worldwide. These drugs can be prescribed not merely according to the relevant symptom, but also according to the diagnosed disease. An increase in the number of patients that has due to an aging population, the aggressive investment and marketing of the global pharmaceuticals, the drug market for voiding-related symptoms has experienced annual growth.
The global Urology Drugs market is segregated on the basis of Application as Hospital, Clinic, and Others. Based on Type the global Urology Drugs market is segmented in Α (alpha)-blockers and 5 α-reductase inhibitors.
The global Urology Drugs market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Urology Drugs market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Astellas, Endo, GP Pharm, Tolmar, and others are among the major players in the global Urology Drugs market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Urology Drugs Market has been segmented as below:
Urology Drugs Market, By Application
Urology Drugs Market, By Type
Urology Drugs Market, By Region
Urology Drugs Market, By Company
The report covers:
Report Scope:
The global Urology Drugs market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Urology Drugs market share. Major industry players with significant revenue share include Astellas, Endo, GP Pharm, Tolmar and others.
Reasons to Buy this Report:
Customization
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach – Segmental Market Analysis
2.5.2 Top-Down Approach – Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter’s Five Force Analysis
5. Urology Drugs Market, By Application
5.1 Introduction
5.2 Hospital
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Clinic
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Others
5.4.1 Market Overview
5.4.2 Market Size and Forecast
6. Urology Drugs Market, By Type
6.1 Introduction
6.2 Α (alpha)-blockers
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 5 α-reductase inhibitors
6.3.1 Market Overview
6.3.2 Market Size and Forecast
7. Urology Drugs Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 North America Urology Drugs, By Application
7.2.2 North America Urology Drugs, By Type
7.3 Europe
7.3.1 Europe Urology Drugs, By Application
7.3.2 Europe Urology Drugs, By Type
7.4 Asia-Pacific
7.4.1 Asia-Pacific Urology Drugs, By Application
7.4.2 Asia-Pacific Urology Drugs, By Type
7.5 Rest of the World
7.5.1 Rest of the World Urology Drugs, By Application
7.5.2 Rest of the World Urology Drugs, By Type
8. Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
9. Company Profiles
9.1 Astellas
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 Endo
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 GP Pharm
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 Tolmar
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
The Urology Drugs Market has been segmented as below:
Urology Drugs Market, By Application
Urology Drugs Market, By Type
Urology Drugs Market, By Region
Urology Drugs Market, By Company
SUBSCRIBE TO OUR NEWSLETTERS
